Tyra Biosciences Inc TYRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
-
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
-
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
-
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
Trading Information
- Previous Close Price
- $19.04
- Day Range
- $18.26–19.09
- 52-Week Range
- $13.35–40.65
- Bid/Ask
- $18.55 / $18.56
- Shares Outstanding
- 68.76M
- Market Cap
- $1.27B
- Volume/Avg
- 648,973 / 839,832
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 87
- Website
- https://www.tyra.bio
Valuation
|
Metric
|
TYRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
TYRA
Financial Strength
|
Metric
|
TYRA
|
|---|---|
Quick Ratio | 14.38 |
Current Ratio | 14.91 |
Interest Coverage | — |
Quick Ratio
TYRA
Profitability
|
Metric
|
TYRA
|
|---|---|
Return on Assets (Normalized) | −33.88% |
Return on Equity (Normalized) | −36.41% |
Return on Invested Capital (Normalized) | −39.44% |
Return on Assets
TYRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|mhcjW@ | LOCK|&^<W | $127B | |||
| Moderna Inc
MRNA
| LOCK|plGX#< | LOCK|k! | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|GQp?>P& | LOCK|l#Vw | $81B | |||
| argenx SE ADR
ARGX
| LOCK|sg$%%c^ | LOCK|?g | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|K<#>r@Y | LOCK|hL@ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|k$C&Tx | LOCK|MQ^&T | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#@@!GJR& | LOCK|&<@x | $27B | |||
| Incyte Corp
INCY
| LOCK|!<pqRdh | LOCK|yk | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Gxg<W%@ | LOCK|cF$ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|C?$$Z?l | LOCK|zm& | $14B |
United States